Efficacy and safety of extracorporeal membrane oxygenation-supported percutaneous coronary intervention in chronic coronary total occlusion patients with reduced left ventricular ejection fraction.
10.3760/cma.j.cn112148-20230808-00060
- VernacularTitle:ECMO辅助下对LVEF明显降低冠心病患者CTO病变行PCI的疗效和安全性
- Author:
Shao Yi GUAN
1
;
Zhen Yang LIANG
1
;
Miao Han QIU
1
;
Hai Wei LIU
1
;
Kai XU
1
;
Ying Yan MA
1
;
Bin WANG
1
;
Quan Min JING
1
;
Ya Ling HAN
1
Author Information
1. Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
- Publication Type:Journal Article
- MeSH:
Male;
Humans;
Stroke Volume;
Ventricular Function, Left;
Extracorporeal Membrane Oxygenation;
Percutaneous Coronary Intervention;
Heart;
Vascular Diseases
- From:
Chinese Journal of Cardiology
2023;51(9):984-989
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the feasibility and safety of extracorporeal membrane oxygenation (ECMO)-supported percutaneous coronary intervention (PCI) in chronic coronary total occlusion (CTO) patients with reduced left ventricular ejection fraction (LVEF). Methods: The CTO patients with LVEF≤35% and undergoing CTO-PCI assisted by ECMO in the General Hospital of Northern Theater Command from December 2018 to March 2022 were enrolled in this study. The post-procedure complications, changes of LVEF from pre-procedure to post-procedure during hospitalization, and the incidence of all-cause mortality and changes of LVEF after discharge were assessed. Results: A total of 17 patients aged (59.4±11.8) years were included. There were 14 males. The pre-procedure LVEF of these patients were (29.00±4.08)%. Coronary angiography results showed that there were 29 CTO lesions in these 17 patients. There was 1 in left main coronary artery, 7 in left anterior descending artery, 11 in left circumflex artery, and 10 in right coronary artery. ECMO was implanted in all patients before procedure. Among 25 CTO lesions attempted to cross, 24 CTO were successfully implanted with stents. All patients underwent successful PCI for at least one CTO lesion. The number of drug-eluting stents implantation per patient were 4.6±1.3. After procedure, there were 8 patients with hemoglobin decreased>20 g/L, and 1 patient with ECMO-access-site related bleeding. The LVEF value at a median duration of 2.5 (2.0-5.5) days after procedure significantly increased to (38.73±7.01)% (P<0.001 vs. baseline). There were no in-hospital deaths. Patients were followed up for 360 (120, 394) days after discharge, 3 patients died (3/17). The LVEF value was (41.80±7.32)% at 155 (100, 308) days after discharge, which was significantly higher than the baseline value (P<0.001). Conclusion: The results of present study demonstrate that it is feasible, efficient and safe to perform ECMO)-supported CTO-PCI in CTO patients with reduced LVEF.
